Table 2.

Representative clinical trials of vaccine therapy in glioma.

Registration number	New/recurrent/metastatic	Therapy	Number of patients	Phase
EGFRvIII vaccine
NCT01480479	New	Rindopepimut/GM-CSF	n = 700	Phase III
NCT00626015	New	EGFRvIII peptide vaccine, daclizumab	3 experimental versus 3 control	Pilot
[96]	New	DC vaccine targeting EGFRvIII antigen	n = 12	Phase I
[38]	New	EGFRvIII peptide vaccine	n = 18	Phase II
[39]	New	EGFRvIII peptide Vaccine, TMZ	n = 22	Phase II
[40]	New	Rindopepimut (CDX-110)	n = 65	Phase II
Heat-shock protein (HSP) vaccine
NCT01814813	Recurrent	HSPPC-96 C, bevacizumab	n = 222	Phase II
[54]	Recurrent	HSPPC-96 vaccine	n = 41	Phase II
[97]	New	HSP70 vaccine	n = 12	Pilot
Dendritic cell (DC) vaccines
NCT00846456	New	DC vaccine against cancer stem cells	n = 11	Pilot
NCT00068510	New + recurrent	C vaccine, toll-like receptor agonists	n = 23	Phase I
NCT00045968	New	DCVax®-L	n = 300	Phase III
[98]	New	DC vaccine	n = 10	Pilot
[99]	New	DC vaccine	n = 8	Pilot
[100]	New	DC vaccine	n = 5	Pilot
[101]	Recurrent	DC vaccine	n = 9	Phase I
[47]	New + recurrent	multi-epitope pulsed DC vaccine	n = 21	Phase I
[102]	New + recurrent	DC vaccine	n = 17	Phase I/II
Adoptive T-cell therapy
NCT02209376	New + recurrent	CAR T-cells to EGFRvIII	n = 12	Phase I
NCT00693095	New	CMV-autologous lymphocyte transfer	n = 12	Phase I
NCT01109095	Recurrent	CMV-specific cytotoxic T lymphocytes	n = 16	Phase I
NCT01454596	Recurrent	CAR T-cells to EGFRvIII	n = 160	Phase I/II
NCT02208362	Recurrent + refractory	Enriched T-cells expressing IL13Ra2	n = 44	Phase I
[93]	Recurrent	CMV-specific T-cells	n = 19	Phase I